Inotersen + Placebo
Phase 2/3Completed 0 watching 0 views this week📈 Rising
62
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
FAP
Conditions
FAP, Familial Amyloid Polyneuropathy, TTR, Transthyretin, Amyloidosis
Trial Timeline
Mar 15, 2013 → Nov 7, 2017
NCT ID
NCT01737398About Inotersen + Placebo
Inotersen + Placebo is a phase 2/3 stage product being developed by Ionis Pharmaceuticals for FAP. The current trial status is completed. This product is registered under clinical trial identifier NCT01737398. Target conditions include FAP, Familial Amyloid Polyneuropathy, TTR.
Hype Score Breakdown
Clinical
22
Activity
15
Company
7
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01737398 | Phase 2/3 | Completed |
Competing Products
2 competing products in FAP